Verici Dx plc

Equities

VRCI

GB00BM8HZD43

Medical Equipment, Supplies & Distribution

Delayed London S.E. Other stock markets 08:08:29 2024-07-03 EDT			5-day change	1st Jan Change
6.78 ^GBX	+0.44%		+4.31%	-30.46%

07-01	Verici Dx hails milestone payment in deal with Thermo Fisher	AN
06-18	EARNINGS AND TRADING: Cordel thrilled by Middle East contract win	AN

Verici Dx hails milestone payment in deal with Thermo Fisher

July 01, 2024 at 09:28 am

Verici Dx PLC - develops advanced clinical diagnostics for organ transplants - Notes that Thermo Fisher Scientific Inc confirms the completion of the transfer and achievement of all transfer-related activities for the pre-transplant prognostic testing technology licensed by Verici to Thermo under an agreement signed in November. The event triggers a milestone payment, Verici highlights.

Verici Chief Executive Officer Sara Barrington says: "I am delighted to announce this smooth transition between Verici Dx and Thermo Fisher Scientific. This collaboration brings together Verici Dx's innovative technology into Thermo Fisher's new CLIA laboratory in the US, which will ultimately benefit patients and the field of organ transplantation." CLIA refers to the Clinical Laboratory Improvement Amendments of 1988 in the US, which requires performing examinations of human specimens for certain purposes to be certified by the secretary of the Department of Health & Human Services.

Current Verici stock price: 6.73 pence per share, up 7.6% on Monday afternoon in London

12-month change: down 49%

Current Thermo Fisher stock price: USD553.00 each in New York

12-month change: up 6.5%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	THERMO FISHER SCIENTIFIC	534.9 USD	+0.19%	-4.06%	204B
	VERICI DX PLC	6.78 GBX	+0.44%	+4.31%	20.76M

Latest news about Verici Dx plc

Verici Dx hails milestone payment in deal with Thermo Fisher	07-01	AN
EARNINGS AND TRADING: Cordel thrilled by Middle East contract win	06-18	AN
Verici Dx plc Announces Successful Transfer of Urine Samples to Thermo Fisher Scientific	06-18	CI
Verici Dx launches educational website for kidney transplant patients	05-31	AN
Verici Dx Announces Launch of Patient-Focused Educational Tool	05-31	CI
EARNINGS AND TRADING: Lowland beats benchmark; EnQuest output in line	05-30	AN
Earnings Flash (VRCI.L) VERICI DX Reports FY23 Revenue $1M	05-30	MT
Earnings Flash (VRCI.L) VERICI DX Posts FY23 Loss $-0.05	05-30	MT
Verici Dx plc Reports Earnings Results for the Full Year Ended December 31, 2023	05-30	CI
Verici DX raises GBP280,000 via retail offer, adding to placing raise	02-14	AN
Verici Dx Raises GBP6.5 Million Via Placing, Retail Offer	02-14	MT
EARNINGS AND TRADING: Asia Strategic loss narrows; Verici Dx grant win	01-31	AN
Verici Dx plc Announces New Research Initiative	01-31	CI
Verici Dx to Raise GBP280,000 via Retail Offer	01-25	MT
Diversified Energy criticises "opportunistic" report	01-24	AN
Verici shares fall after completing discounted GBP5.5 million placing	01-24	AN
Verici Dx Proposes Placing, Conditional Retail Offer; Shares Down	01-24	MT
Verici up after US health agency confirms pricing rate for blood tests	01-08	AN
Verici Dx plc Announces Medicare National Payment Rate for Tutiviatm and Claravatm Effective as of January 1, 2024	01-08	CI
Verici Dx hails publication of Tutivia data in transplant journal	12-11	AN
Verici gets ISO 27001 seal for information management security system	11-29	AN
UK inflation slowdown lifts retail and property	11-15	AN
AIM WINNERS & LOSERS: Verici Dx rockets on Thermo Fisher contract	11-15	AN
Verici Dx, Thermo Fisher Sign Exclusive License Deal for Pre-transplant Prognostic Testing; Shares Soar	11-15	MT
Verici Dx shares jump on signing Thermo Fisher assay development deal	11-15	AN

Chart Verici Dx plc

Duration

Period

More charts

Company Profile

Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-09-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Verici Dx plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0675 GBP

Average target price

0.2 GBP

Spread / Average Target

+196.30%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
VERICI DX PLC	-30.46%	20.76M
BIOMÉRIEUX	-10.24%	11.38B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-19.13%	6.83B
DIASORIN S.P.A.	+6.50%	5.52B
LANTHEUS HOLDINGS, INC.	+26.61%	5.44B
AUTOBIO DIAGNOSTICS CO., LTD.	-20.49%	3.62B
ANDON HEALTH CO., LTD.	+6.88%	2.56B
10X GENOMICS, INC.	-66.28%	2.26B
MYRIAD GENETICS, INC.	+29.36%	2.24B
VITROLIFE AB	-12.48%	2.13B

Diagnostic & Testing Substances